Physician profile
Matthew Wadas
NPI 1821448358
$16,616.47
in general payments reported to CMS, 2019-2025
21 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $718 · 2021: $483 · 2022: $12K · 2023: $955 · 2024: $893 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10,330.89 | 2019-2022 | |
| Abbvie INC. | $1,257.91 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Kala Pharmaceuticals, INC. | $864.90 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $859.78 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $828.48 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $643.98 | 2021-2025 | Precision 1, Precision7, Rocklatan |
| Tearlab Corp | $377.33 | 2020 | |
| Coopervision INC. | $266.71 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Tarsus Pharmaceuticals, INC. | $224.30 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $186.52 | 2020-2023 | |
| Oyster Point Pharma, INC. | $136.55 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $125.00 | 2019 | |
| Astellas Pharma US INC | $124.99 | 2023 | |
| Optos, INC. | $106.64 | 2020 | |
| Sight Sciences, INC. | $85.02 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $52.09 | 2022-2023 | |
| Dompe US, INC. | $48.25 | 2021-2024 | Oxervate |
| Harrow Eye, LLC | $47.11 | 2024 | Vevye |
| Biotissue Holdings INC. | $23.53 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.01 | 2021 | |
| Shire North American Group INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.